Does Missouri Medicaid Cover Zepbound? PA, Denials, and Appeals

Yes, Missouri Medicaid does cover Zepbound. MO HealthNet lists Zepbound (tirzepatide) as a preferred agent for obesity on its Preferred Drug List, which means many prescriptions can be approved at the pharmacy counter without a separate prior authorization form.¹

How Coverage Works at the Pharmacy

Because Zepbound has preferred status, MO HealthNet uses what it calls a “transparent approval.” If your prescriber puts a valid, billable ICD-10 obesity diagnosis code on the pharmacy claim, the system can process the prescription at the point of sale with no separate paperwork.² Without that diagnosis code on the claim, a standard prior authorization based on clinical criteria is required instead.

A few utilization rules apply to everyone:

Only one GLP-1 claim will pay per month.
When switching medications or doses, you must use your current prescription for at least 23 days before a new claim will process.³
Moving up to a higher Zepbound dose does not require a new prior authorization.

Pharmacists cannot add or change a diagnosis for this drug class on their own. MO HealthNet has warned that altering diagnosis codes to work around the rules can trigger audits, claim recoupment, or administrative action.²

When Prior Authorization Is Required

If a PA is needed, your prescriber submits it with recent chart notes documenting your height and weight. For patients with a BMI of 27 to 29.9, the PA must also document at least one weight-related comorbidity.³ Those thresholds track the FDA-approved indication for Zepbound: adults with a BMI of 30 or greater, or a BMI of 27 or greater with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnea, or cardiovascular disease.⁴

Providers file PA requests on the Drug Prior Authorization Request form from the MO HealthNet pharmacy portal. The state recommends the current fillable PDF and typed entries. Completed forms can be faxed to (573) 636-6470, or the request can be called in at (800) 392-8030, option 3.³

If You Were Taking Mounjaro for Weight Loss

MO HealthNet participants who had been using Mounjaro for obesity are required to switch to Zepbound. Both drugs contain the same active ingredient, tirzepatide, in the same strengths and forms. Patients with recent compliance on Mounjaro are approved for Zepbound automatically, so no new PA is required for the switch.² The transition applies specifically to Mounjaro use for obesity; the policy does not indicate that patients on Mounjaro for diabetes are affected.

Wegovy Is Not a Backup Option

If Zepbound doesn’t work out, don’t assume Wegovy will step in. On MO HealthNet, Wegovy (semaglutide) is non-preferred and is covered only to reduce major adverse cardiovascular events, not for obesity generally. Its PA requirements are stricter: age 45 or older, BMI of 27 or greater, a history of major adverse cardiovascular events, and confirmed absence of diabetes with an HbA1c below 6.5% in the past three months. Initial Wegovy approvals run only four weeks at a time.⁵ Ozempic, Trulicity, and Victoza are preferred, but only under the separate diabetes category.²

Adolescent Patients

MO HealthNet allows off-label use of Zepbound for adolescent participants who need obesity treatment. The same framework applies: a billable diagnosis code on the claim, the one-GLP-1-per-month limit, and the 23-day utilization rule. Ozempic is available off-label for adolescent obesity on the same terms.³

If You Have Both Medicare and Medicaid

Coverage is more complicated for dual-eligible participants. MO HealthNet will not pay as the primary payer for GLP-1 medications, and Medicaid can only sit behind Medicare as secondary.³ Medicare Part D currently excludes drugs used solely for weight loss, so Zepbound is covered under Part D only when it’s prescribed for an FDA-approved non-weight-loss indication, such as moderate to severe obstructive sleep apnea in adults with obesity, and only if it’s on that plan’s formulary.⁶ In practice, many dual-eligible patients cannot get Zepbound for obesity through either program right now. A federal short-term demonstration is scheduled to open Medicare Part D access to obesity drugs beginning in July 2026, with a broader model expected in January 2027.⁷

What to Do if Your Prescription Is Denied

You have appeal rights if MO HealthNet or a managed care plan denies your Zepbound prescription. The appeal must be filed within 60 days of the denial notice. If you’re in a managed care plan, contact your plan’s member representative by phone or mail using the instructions in your member handbook. After you finish the plan-level appeal, you can request a State Fair Hearing for further review.⁸

One note on cost while you’re sorting coverage out: Eli Lilly’s savings programs for Zepbound explicitly exclude government beneficiaries, including Medicaid, Medicare, and TRICARE, so cash-pay and coupon options aren’t a workaround if you’re enrolled in MO HealthNet.⁹ For participants with approved coverage, the drug is paid through the Medicaid pharmacy benefit.

1
Missouri Department of Social Services. MO HealthNet Preferred Drug List
2
Missouri Department of Social Services. MO HealthNet GLP-1 Receptor Agonists Indicated for Obesity PDL Edit
3
LecturePanda. MO HealthNet Pharmacy Program Update
4
U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management
5
Missouri Academy of Family Physicians. Adult Obesity Medications
6
Wellcare. Does Medicare Cover Weight Loss Drugs
7
KFF. Medicaid Coverage of and Spending on GLP-1s
8
MO Health Portal. Appeals and Grievances
9
Eli Lilly. Zepbound Coverage and Savings